Company*
(Country; Symbol)
Company
(Country; Symbol)
Type/Product Area Terms/Details (Date)

I. MODIFIED AGREEMENTS
 
APRIL
 
Alseres Pharmaceuticals Inc. (ALSE) BioAxone Therapeutic Inc.*  (Canada) Amended agreement for Cethrin and Rho inhibitor technology If Alseres fails to sub-license its rights under the Cethrin license within a specified time period, the company retains a right to receive a smaller portion of any license revenue that BioAxone generates after the Cethrin license terminates (4/30)
 
Cangene Corp. (Canada; TSX:CNJ) Apotex Group* (Canada) Revised deal giving Cangene the rights to commercialize its pipeline of recombinant products The two parties will share the right to market Leucotropin and Accretropin, and Cangene's royalty on Ferriprox (deferiprone) will be phased out over three years (4/16)
 
MAY
 
Argenta Discovery Ltd.* Genentech Inc. Extended drug discovery agreement for two years The agreement covers a number of drug discovery programs that use Argenta's computer-aided drug design, medicinal chemistry and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech (5/20)
 
II. TERMINATED AGREEMENTS
 
XenoPort Inc. (XNPT) Xanodyne Pharmaceuticals Inc.* Terminated partnership for the development of XP21510, a preclinical drug for menorrhagia XenoPort had thus far received $12M up front and $1M out of a potential $129M in milestone payments; rights to XP21510 will return to XenoPort (4/2)

Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

TSX = Toronto Stock Exchange; SWX = Swiss Stock Exchange.